Free Trial

Sera Prognostics (SERA) Competitors

Sera Prognostics logo
$3.13 -0.32 (-9.28%)
Closing price 04/3/2025 04:00 PM Eastern
Extended Trading
$3.14 +0.00 (+0.16%)
As of 04:08 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SERA vs. AUNA, FLGT, EHAB, TALK, INNV, CELC, SBC, PSNL, VMD, and DCGO

Should you be buying Sera Prognostics stock or one of its competitors? The main competitors of Sera Prognostics include Auna (AUNA), Fulgent Genetics (FLGT), Enhabit (EHAB), Talkspace (TALK), InnovAge (INNV), Celcuity (CELC), SBC Medical Group (SBC), Personalis (PSNL), Viemed Healthcare (VMD), and DocGo (DCGO). These companies are all part of the "healthcare" industry.

Sera Prognostics vs.

Sera Prognostics (NASDAQ:SERA) and Auna (NYSE:AUNA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, analyst recommendations, valuation, dividends and community ranking.

Sera Prognostics received 3 more outperform votes than Auna when rated by MarketBeat users. However, 100.00% of users gave Auna an outperform vote while only 38.46% of users gave Sera Prognostics an outperform vote.

CompanyUnderperformOutperform
Sera PrognosticsOutperform Votes
10
38.46%
Underperform Votes
16
61.54%
AunaOutperform Votes
7
100.00%
Underperform Votes
No Votes

In the previous week, Auna had 3 more articles in the media than Sera Prognostics. MarketBeat recorded 3 mentions for Auna and 0 mentions for Sera Prognostics. Auna's average media sentiment score of 1.25 beat Sera Prognostics' score of 0.00 indicating that Auna is being referred to more favorably in the news media.

Company Overall Sentiment
Sera Prognostics Neutral
Auna Positive

54.6% of Sera Prognostics shares are owned by institutional investors. 15.8% of Sera Prognostics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Sera Prognostics has higher earnings, but lower revenue than Auna. Sera Prognostics is trading at a lower price-to-earnings ratio than Auna, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sera Prognostics$77K1,531.02-$36.24M-$0.99-3.16
Auna$4.39B0.12-$67.90M$0.3818.34

Auna has a consensus price target of $13.53, suggesting a potential upside of 94.05%. Given Auna's higher possible upside, analysts plainly believe Auna is more favorable than Sera Prognostics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sera Prognostics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Auna
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00

Auna's return on equity of 0.00% beat Sera Prognostics' return on equity.

Company Net Margins Return on Equity Return on Assets
Sera PrognosticsN/A -51.73% -36.94%
Auna N/A N/A N/A

Summary

Auna beats Sera Prognostics on 10 of the 15 factors compared between the two stocks.

Remove Ads
Get Sera Prognostics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SERA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SERA vs. The Competition

MetricSera PrognosticsMedical laboratories IndustryMedical SectorNASDAQ Exchange
Market Cap$117.89M$2.80B$5.54B$7.50B
Dividend YieldN/A24.77%4.86%4.04%
P/E Ratio-3.1612.9623.2418.08
Price / Sales1,531.02179.56361.2586.83
Price / CashN/A57.5638.1634.64
Price / Book1.424.176.493.99
Net Income-$36.24M-$22.21M$3.21B$247.18M
7 Day Performance-11.58%-3.36%-4.91%-4.25%
1 Month Performance-24.76%3.40%-0.08%-6.87%
1 Year Performance-66.63%-2.32%6.40%-3.73%

Sera Prognostics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SERA
Sera Prognostics
0.4065 of 5 stars
$3.13
-9.3%
N/A-66.9%$117.89M$77,000.00-3.16120Gap Down
AUNA
Auna
3.9102 of 5 stars
$7.11
-2.9%
$13.53
+90.2%
-24.9%$525.56M$4.39B18.7114,958Gap Down
FLGT
Fulgent Genetics
2.7444 of 5 stars
$16.90
-0.9%
$16.00
-5.3%
-19.6%$521.64M$283.47M-3.061,010Short Interest ↑
Positive News
EHAB
Enhabit
1.3594 of 5 stars
$8.82
+2.0%
$8.50
-3.6%
-22.5%$445.08M$1.03B-3.8010,800Positive News
TALK
Talkspace
4.0312 of 5 stars
$2.56
-2.7%
$4.38
+70.9%
-26.6%$431.20M$187.59M256.26500Analyst Forecast
Short Interest ↓
News Coverage
Gap Down
INNV
InnovAge
1.4484 of 5 stars
$2.98
-0.7%
$5.00
+67.8%
-38.5%$403.03M$806.61M-15.682,000Gap Down
CELC
Celcuity
1.4271 of 5 stars
$10.11
-1.3%
$30.17
+198.4%
-55.8%$375.38MN/A-3.8740Earnings Report
Analyst Forecast
Analyst Revision
Gap Down
SBC
SBC Medical Group
N/A$3.19
-2.7%
N/AN/A$328.64M$223.34M0.00N/AEarnings Report
Analyst Revision
Gap Up
PSNL
Personalis
4.1291 of 5 stars
$3.51
-3.0%
$7.80
+122.2%
+144.4%$309.80M$84.61M-2.09400Positive News
Gap Down
VMD
Viemed Healthcare
1.0283 of 5 stars
$7.28
+0.1%
N/A-21.0%$287.72M$224.26M26.96630Positive News
Gap Down
DCGO
DocGo
2.9483 of 5 stars
$2.64
flat
$4.89
+85.3%
-33.2%$269.24M$616.56M9.432,920Short Interest ↓
Gap Down
Remove Ads

Related Companies and Tools


This page (NASDAQ:SERA) was last updated on 4/4/2025 by MarketBeat.com Staff
From Our Partners